We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Read MoreHide Full Article
Key Takeaways
Incyte and Genmab will test INCB161734, petosemtamab and chemotherapy in first-line KRAS G12D-mutated mCRC.
Genmab will lead a phase I/II study, while Incyte supplies INCB161734 and shares development costs.
Incyte is also evaluating INCB161734 in phase III pancreatic cancer and phase I solid tumor studies.
Incyte Corporation (INCY - Free Report) has entered into a clinical trial collaboration with Denmark-based Genmab A/S (GMAB - Free Report) to evaluate a new combination therapy for the first-line treatment of patients with metastatic colorectal cancer (mCRC) carrying the KRAS G12D mutation.
The combination will include INCB161734, Incyte’s investigational KRAS G12D inhibitor, petosemtamab, Genmab’s investigational bispecific antibody and standard chemotherapy.
INCB161734 is an investigational, oral drug designed to selectively block the KRAS G12D mutation, which helps cancer cells grow and survive.
Petosemtamab is a bispecific antibody that targets two proteins, EGFR and LGR5, that play a role in cancer growth and the survival of cancer stem-like cells.
Combining these drugs with chemotherapy could offer a new treatment approach for patients with this type of colorectal cancer.
Under the agreement, Genmab will conduct a phase I/II clinical study evaluating the combination in patients with KRAS G12D-mutated mCRC who have not received prior treatment for their metastatic disease. Incyte will provide INCB161734 and share the development costs with Genmab.
KRAS mutations affect nearly 40% of colorectal cancers, with KRAS G12D being the most common KRAS mutation in this cancer type. According to the companies, the mutation is found in approximately 15% of colorectal cancer cases.
Year to date, Incyte shares have gained 17.1% compared with the industry’s 5.7% growth.
Image Source: Zacks Investment Research
Incyte Advances INCB161734 Development
Incyte is evaluating INCB161734 across several clinical settings involving KRAS G12D-mutated cancers.
The candidate is being studied in the global phase III DAWN-303 study in previously untreated patients with KRAS G12D-mutated pancreatic ductal adenocarcinoma. The study is evaluating INCB161734 in combination with standard chemotherapy to assess its safety and efficacy.
INCB161734 is also being evaluated as a single agent and in combination with chemotherapy in an ongoing phase I study involving patients with KRAS G12D-mutated solid tumors.
More on Genmab’s Petosemtamab
Genmab is developing petosemtamab for several solid tumors, including head and neck squamous cell carcinoma and colorectal cancer.
Petosemtamab is also being evaluated in two late-stage studies in combination with chemotherapy for first- and second-line treatment of RAS/BRAF wild-type metastatic colorectal cancer. The new collaboration with Incyte expands its clinical development into KRAS G12D-mutated mCRC, a distinct patient population.
Some better-ranked stocks in the biotech sector are Halozyme Therapeutics (HALO - Free Report) and TG Therapeutics (TGTX - Free Report) , each sporting a Zacks Rank #1 at present.
Over the past 60 days, earnings per share estimates for Halozyme Therapeutics have increased from $8.37 to $8.80 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $9.75 to $10.29. HALO’s shares have surged 86.7% year to date.
Halozyme Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the negative average surprise being 19.12%.
Over the past 60 days, earnings per share estimates for TG Therapeutics have risen from 92 cents to 94 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from $2.65 to $2.66. TGTX’s shares have risen 81.7% year to date.
TG Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining one, with the average surprise being 184.65%.
View the Zacks #1 Rank List
Image: Bigstock
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
Key Takeaways
Incyte Corporation (INCY - Free Report) has entered into a clinical trial collaboration with Denmark-based Genmab A/S (GMAB - Free Report) to evaluate a new combination therapy for the first-line treatment of patients with metastatic colorectal cancer (mCRC) carrying the KRAS G12D mutation.
The combination will include INCB161734, Incyte’s investigational KRAS G12D inhibitor, petosemtamab, Genmab’s investigational bispecific antibody and standard chemotherapy.
INCB161734 is an investigational, oral drug designed to selectively block the KRAS G12D mutation, which helps cancer cells grow and survive.
Petosemtamab is a bispecific antibody that targets two proteins, EGFR and LGR5, that play a role in cancer growth and the survival of cancer stem-like cells.
Combining these drugs with chemotherapy could offer a new treatment approach for patients with this type of colorectal cancer.
Under the agreement, Genmab will conduct a phase I/II clinical study evaluating the combination in patients with KRAS G12D-mutated mCRC who have not received prior treatment for their metastatic disease. Incyte will provide INCB161734 and share the development costs with Genmab.
KRAS mutations affect nearly 40% of colorectal cancers, with KRAS G12D being the most common KRAS mutation in this cancer type. According to the companies, the mutation is found in approximately 15% of colorectal cancer cases.
Year to date, Incyte shares have gained 17.1% compared with the industry’s 5.7% growth.
Image Source: Zacks Investment Research
Incyte Advances INCB161734 Development
Incyte is evaluating INCB161734 across several clinical settings involving KRAS G12D-mutated cancers.
The candidate is being studied in the global phase III DAWN-303 study in previously untreated patients with KRAS G12D-mutated pancreatic ductal adenocarcinoma. The study is evaluating INCB161734 in combination with standard chemotherapy to assess its safety and efficacy.
INCB161734 is also being evaluated as a single agent and in combination with chemotherapy in an ongoing phase I study involving patients with KRAS G12D-mutated solid tumors.
More on Genmab’s Petosemtamab
Genmab is developing petosemtamab for several solid tumors, including head and neck squamous cell carcinoma and colorectal cancer.
Petosemtamab is also being evaluated in two late-stage studies in combination with chemotherapy for first- and second-line treatment of RAS/BRAF wild-type metastatic colorectal cancer. The new collaboration with Incyte expands its clinical development into KRAS G12D-mutated mCRC, a distinct patient population.
INCY’s Zacks Rank & Stocks to Consider
Incyte has a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the biotech sector are Halozyme Therapeutics (HALO - Free Report) and TG Therapeutics (TGTX - Free Report) , each sporting a Zacks Rank #1 at present.
Over the past 60 days, earnings per share estimates for Halozyme Therapeutics have increased from $8.37 to $8.80 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $9.75 to $10.29. HALO’s shares have surged 86.7% year to date.
Halozyme Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the negative average surprise being 19.12%.
Over the past 60 days, earnings per share estimates for TG Therapeutics have risen from 92 cents to 94 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from $2.65 to $2.66. TGTX’s shares have risen 81.7% year to date.
TG Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining one, with the average surprise being 184.65%.